Tirzepatide Watchdog — Research Journalhttps://tirzepatidewatchdog.comStructured summaries of the clinical trials behind GLP-1 and peptide treatments.en-usTue, 14 Jul 2026 17:01:43 +0000SURMOUNT-1: tirzepatide once weekly for the treatment of obesityhttps://tirzepatidewatchdog.com/research/surmount-1https://tirzepatidewatchdog.com/research/surmount-1Mean weight change: −15.0% (5mg), −19.5% (10mg), −20.9% (15mg), versus −3.1% with placebo.Tue, 14 Jul 2026 17:01:43 +0000SURMOUNT-5: tirzepatide as compared with semaglutide for the treatment of obesityhttps://tirzepatidewatchdog.com/research/surmount-5https://tirzepatidewatchdog.com/research/surmount-5Tirzepatide −20.2% (95% CI −21.4 to −19.1) versus semaglutide −13.7% (95% CI −14.9 to −12.6), p<0.001. Absolute: 22.8 kg versus 15.0 kg. At least 25% body-weight loss: 31.6% versusTue, 14 Jul 2026 17:01:43 +0000STEP 1: once-weekly semaglutide in adults with overweight or obesityhttps://tirzepatidewatchdog.com/research/step-1https://tirzepatidewatchdog.com/research/step-1Mean weight change −14.9% with semaglutide versus −2.4% with placebo.Tue, 14 Jul 2026 17:01:43 +0000SELECT: semaglutide and cardiovascular outcomes in obesity without diabeteshttps://tirzepatidewatchdog.com/research/selecthttps://tirzepatidewatchdog.com/research/selectA 20% relative reduction in major adverse cardiovascular events (6.5% versus 8.0% absolute). This is the trial that moved semaglutide from a weight-loss drug to a cardiovascular onTue, 14 Jul 2026 17:01:43 +0000